< The 2016 All-Europe Research Team
Sachin Jain, Graham Parry & team
Bank of America Merrill Lynch
First-place appearances: 5
Total appearances: 23
Team debut: 1995
In 2014 and 2015, when coverage of Europe’s biotechnology stocks was included in the Pharmaceuticals category, London-based Sachin Jain and Graham Parry guided their Bank of America Merrill Lynch squad to first place. The sectors are separate now, and these researchers again top the Pharmaceuticals roster while earning the No. 3 position on this Biotechnology lineup. Working out of London, the five-person group reports on seven names in this regional sector, and one of its favorites is Denmark’s Genmab. The drug developer’s anticancer drug Darzalex (daratumumab), for treatment of patients with multiple myeloma, is key to Genmab’s future growth, the researchers believe. In a December report, they advised clients that “we believe the company is entering a new phase with its exciting lead asset daratumumab and strong technology platform, more than offsetting our caution on its only marketed asset Arzerra.” In addition, says Jain, “updated competitor data was underwhelming and continued to suggest a potential best-in-class profile for Darzalex.” Their target price for Genmab is 1,014 Danish kroner, implying a 23.8 percent upside to its trading level in mid-January.
